Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis

doi:10.3748/wjg.15.231

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3591)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-5) series.

Item

Count

PDF

356

HTML

3006

Tables (1-5)

229

Sum=3591

Jan 14, 2009 (publication date) through Feb 9, 2025

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Gastroenterol. Jan 14, 2009; 15(2): 231-239
Published online Jan 14, 2009. doi: 10.3748/wjg.15.231

Table 5 Therapy and outcome of reported cases of hepatocellular carcinoma associated with autoimmune hepatitis and primary biliary cirrhosis, compared to cases of general hepatocellular carcinoma in Japan

Clinical status	Compiled numbers (%)			P-values
Clinical status	HCC patients with AIH (AIH-series)	HCC patients with PBC (PBC-series)	General-HCC patients	AIH-series/General-HCC patients	PBC-series/General-HCC patients	AIH-series/PBC-series
Therapy choices for HCC	Total: 38	Total: 47	Total: 17005	Operation vs CL or TAE P = 0.048¹	RFA, PEIT vs CL or TAE
CL or TAE	18 (47.4)	17 (36.2)	4636 (27.2)	RFA,PEIT,MCT vs	P = 0.027¹
Operation	8 (21.0)	16 (34.0)	5268 (31.0)	CL or TAE	RFA, PEIT vs
RFA, PEIT, MCT	6 (15.8)	6 (12.8)	4890 (28.8)	P = 0.018¹	No therapy
Chemotherapy	0 (0)	0 (0)	765 (4.5)	RFA,PEIT,MCT vs	P = 0.003²
Others	0 (0)	0 (0)	122 (0.7)	No therapy
No therapy	6 (15.8)	8 (17.0)	1324 (7.8)	P = 0.038¹
Clinical outcome	Total: 37	Total: 49	Total: 16646
Alive	20 (54.1)	31 (63.3)	13946 (83.8)	P < 0.001^b	P < 0.001^b	P = 0.389
Dead	17 (45.9)	18 (36.7)	2700 (16.2)
Cause of death	Total: 16	Total: 18	Total: 2700	Neoplastic death vs variceal rupture P = 0.050¹ Cancer death vs GI bleeding P = 0.013¹	Neoplastic death vs variceal rupture P = 0.050¹
Liver failure	8 (50.0)	8 (44.4)	581 (21.5)
HCC rupture	3 (18.8)	4 (22.2)	172 (6.4)
Variceal rupture	1 (6.2)	1 (5.6)	85 (3.1)
GI bleeding	1 (6.2)	2 (11.1)	55 (2.0)
Neoplastic death	0 (0)	0 (0)	1487 (55.1)
Others	3 (18.8)	3 (16.7)	320 (11.9)

^bP < 0.01, Statistically significant.

¹The calculated P-values did not reach statistical significance with Bonferroni correction; without the correction, however, P-values were below 0.05.

²The calculated P-values reached statistical significance with Bonferroni correction. HCC: Hepatocellular carcinoma; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; CL: Chemolipiodolization; TAE: Transcatheter arterial embolization; RFA: Radiofrequency ablation therapy; PEIT: Percutaneous ethanol injection therapy; MCT: Microwave coagulation therapy; GI: Gastrointestinal.

Citation: Watanabe T, Soga K, Hirono H, Hasegawa K, Shibasaki K, Kawai H, Aoyagi Y. Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroenterol 2009; 15(2): 231-239
URL: https://www.wjgnet.com/1007-9327/full/v15/i2/231.htm
DOI: https://dx.doi.org/10.3748/wjg.15.231